CRC Research Update — May 13, 2026
Today's colorectal cancer research highlights
braf
A collection of 13 issues
CRC Research Update — May 12, 2026
Today's colorectal cancer research highlights
Prolonged Response to Pembrolizumab in BRAF V600E MSS Colorectal Cancer
Skip to content
The CRC Digest
Prolonged Response to Pembrolizumab in BRAF V600E MSS Colorectal Cancer
A patient with BRAF V600E-mutant microsatellite-stable metastatic colorectal cancer achieved a prolonged response to pembrolizumab following a dynamic increase in tumor mutational burden. (The Oncologist)
This content is informational only and does not constitute